PATUSKY CHRISTOPHER 4

What Happened
Christopher Patusky, a director of United Therapeutics (UTHR), exercised stock options and immediately sold the resulting 2,910 shares on April 24, 2026. He exercised options at $101.80 per share (cost $296,238) and sold the 2,910 shares in an open-market transaction at $569.00 per share for total proceeds of $1,655,790. The filing also records a $0 derivative disposal entry associated with the option conversion (see Key Details).

Key Details

• Transaction date: 2026-04-24. Exercise: 2,910 shares @ $101.80 (acquired) — $296,238. Sale: 2,910 shares @ $569.00 (disposed) — $1,655,790.
• Filing footnote: The exercise and subsequent sale were made pursuant to a Rule 10b5-1 trading plan entered into on December 18, 2025.
• The Form 4 shows an additional derivative "Disposed" line at $0 for 2,910 shares, which typically records the conversion/disposition of the option upon exercise and does not reflect a separate cash sale.
• Shares owned after the transactions are not stated in the provided filing excerpt.
• Filing timeliness: Reported and filed on the same date (2026-04-24), indicating a timely Form 4.

Context
This was an option exercise followed by an immediate open-market sale (often a cashless exercise/sale). Because the trades were executed under a pre-established 10b5-1 plan, they are generally considered routine trading pursuant to a prior plan rather than necessarily a contemporaneous expression of view about the company.